BiotechTube
Persevere Therapeutics

Persevere Therapeutics

Cambridge, United States· Est.
perseveretherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5M

Overview

Persevere Therapeutics, founded in 2019 and based in Cambridge, USA, is a private, clinical-stage biotech focused on oncology. Its lead candidate, misetionamide, is a first-in-class small molecule with a dual mechanism inhibiting c-MYC and NFκB, disrupting cancer cell energy metabolism and proliferation. The company has advanced misetionamide into Phase 1b/2a clinical trials and has secured seed financing to support development in ovarian and pancreatic cancers. Persevere's approach leverages a tumor-type agnostic, cancer cell-selective platform with potential for combination therapies.

Oncology

Technology Platform

Dual-mechanism small molecule platform targeting oncogenic transcription factors c-MYC and NFκB to selectively disrupt cancer cell energy metabolism (aerobic glycolysis) and proliferation.

Funding History

1
Total raised:$5M
Seed$5M

Opportunities

The tumor-agnostic potential of its lead asset, misetionamide, offers a path to expand into multiple oncology indications beyond the initial focus on ovarian and pancreatic cancers.
Demonstrating synergy with existing standard-of-care chemotherapies and immunotherapies could position the drug as a valuable combination partner, accelerating clinical adoption and partnership opportunities.

Risk Factors

The primary risk is clinical failure in ongoing or future trials, as the novel dual mechanism, while promising preclinically, remains unproven in later-stage human studies.
As a pre-revenue, private company, Persevere is highly dependent on raising additional capital in a competitive funding environment to advance its clinical programs, creating significant financial and dilution risk.

Competitive Landscape

Persevere operates in the highly competitive oncology space, competing with large pharma and biotech companies developing targeted therapies, immunotherapies, and metabolic inhibitors. Its differentiation lies in its unique dual MOA targeting c-MYC and NFκB, a niche with few direct competitors, but it must still prove clinical superiority or complementary benefit against established standards of care.

More companies in Small Molecule Drugs →More companies in United States →